Which ablation works best for AFib with heart failure? new trial aims to find out
NCT ID NCT07153718
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study compares three catheter ablation strategies in 300 adults with persistent atrial fibrillation and heart failure. The goal is to see which approach best reduces the risk of death, hospitalization, or urgent visits due to worsening heart failure. Participants are randomly assigned to one of three ablation procedures, and their heart rhythm and outcomes are tracked over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- catheter ablation (a procedure to destroy abnormal heart tissue causing irregular rhythm)
- What this could lead to
- If successful, this could identify the best ablation approach to improve survival and reduce hospitalizations for people with both atrial fibrillation and heart failure.
- What could go wrong
- This is a mid-stage trial with 300 participants, so results may not apply to everyone. Ablation carries risks like bleeding, infection, or heart rhythm complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
300 people
The number who actually took part.
- Started
-
Jan 2021
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All inclusion criteria must be met to be included in the study. 1. Age: Patients aged 18-80 years, with persistent atrial fibrillation (AF) and heart failure (HF), regardless of ejection fraction (EF). 2. Diagnosis of Heart Failure: Heart Failure with Reduced Ejection Fraction (HFrEF): LVEF ≤ 40%. Heart Failure with Preserved Ejection Fraction (HFpEF): LVEF \> 40%, including HFmrEF (LVEF 41-50%). 3. Symptomatic Atrial Fibrillation: Patients with symptomatic persistent AF who have failed or are intolerant to at least one antiarrhythmic drug. 4. NYHA Class II-III: Patients with heart failure classified as NYHA class II-III, who are symptomatic despite optimal medical therapy. Informed Consent: Able to provide written informed consent for participation in the study. 5. Guideline-Recommended Pharmacologic Therapy: Patients who have received and are currently on guideline-recommended pharmacologic therapy for heart failure, including but not limited to ACE inhibitors, beta-blockers, diuretics, and mineralocorticoid receptor antagonists (MRAs). Exclusion Criteria: * Any of the following criteria shall be excluded. 1. End-Stage Heart Failure: Patients with heart failure classified as NYHA class IV or with LVEF ≤ 20%. 2. Severe Comorbidities: 3. Patients with severe pulmonary disease (e.g., COPD, severe restrictive lung disease). 4. Severe renal dysfunction (eGFR \< 30 mL/min/1.73m²) or advanced liver disease. 5. Active malignancy or other terminal illnesses with a prognosis of less than one year. 6. Inability to Tolerate Ablation: <!-- --> 1. Patients unable to undergo catheter ablation due to anatomical or procedural issues. 2. Patients with contraindications to the procedure, including allergy to contrast agents or inability to tolerate anesthesia. 3. Left atrial thrombus confirmed by preoperative esophageal ultrasound; 7. Uncontrolled Arrhythmias: Patients with persistent or paroxysmal AF who are unable to maintain sinus rhythm despite optimal medical therapy or require frequent hospitalization for arrhythmia control. 8\. Pregnancy: Pregnant or breastfeeding women. 9. Contraindications to Anticoagulation: 10. Patients who are contraindicated for anticoagulation therapy (e.g., history of major bleeding or bleeding diathesis). 11\. History of Severe Valve Disease: Patients with a history of severe valve disease and/or prosthetic valve replacement. 12\. Recent Myocardial Infarction or Stroke: Patients who have had a myocardial infarction or stroke within the past 3 months. 13\. Contrast Agent Allergy: Patients with a known allergy to contrast agents. 14. Contraindications for Cardiac Catheterization: Any contraindications for cardiac catheterization, including inability to safely perform the procedure. 15\. Atrial Fibrillation Ablation: Patients who have previously undergone atrial fibrillation ablation. 16\. Cardiac Surgery: Patients who have undergone any cardiac surgery within the last 2 months. 17\. Life Expectancy: Patients with a life expectancy of less than 1 year.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Jining Medical University
Jining, Shandong, 272000, China
-
Changshu Hospital of Traditional Chinese Medicine
Changshu, Jiangsu, 215516, China
-
Jinan City People's Hospital
Jinan, Shandong, 271100, China
-
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, 200127, China
-
Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Jinan, Shandong, 250000, China
-
Shanghai Jiao Tong University School of Medicine, Shanghai Chest Hospital
Shanghai, 200030, China
-
The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430014, China
-
The PLA Navy Anqing Hospital
Anqing, Anhui, 246000, China
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, 221009, China
-
Yuhuan Second People's Hospital
Yuhuan, Zhejiang, 317600, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two ways to quiet a racing heart: trial pits hybrid ablation against standard catheter treatment
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?